Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 20 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Metoprolol Tartrate Tablets in various dosages. This medication is used to treat high blood pressure and other heart-related conditions. The tablets will be manufactured at the company's facility in Baddi, Himachal Pradesh. The press release aims to inform investors and exchange members about this significant approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 20, 2023, titled "Zydus receives final approval from the USFDA for Metoprolol Tartrate Tablets USP, 25 mg, 50 mg, and 100 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases